I think people should look into Proteomics (PIQ) as an example...

I think people should look into Proteomics (PIQ) as an example of diagnostics / US healthcare comparison here. PIQ's PromarkerD diabetes diagnostics test is available in the US exclusive through Sonic Healthcare (Market Cap $15B AUD).

Their recent quarterly (announced today) showed $410,000 revenue to date and costs of $1.3M YTD for their operating activities. Now needing to raise $6M via placement.

Comparing to Lumos diagnostics which last quarterly showed $1.338M in revenue YTD and $2.448M costs YTD.

PIQ priced at .91c with 121M shares outstanding (Commsec)

LDX .077c with 480M shares outstanding (Commsec)

Do I think that for the partners in place, the revenue received and incoming, and pipeline available that LDX is substantially undervalued?

Yes.